Deerfield Management MEDP Position
ExitedDeerfield Management exited their position in Medpace Holdings Inc. (MEDP) in Q3 2025, after holding the stock for 2 quarters.
The position was first reported in Q2 2025 and has been tracked across 2 quarterly 13F filings.
2 other tracked funds also hold MEDP.
About Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Full company profile →Short Interest
6.2%
3.7 days to cover
Deerfield Management MEDP Position History
Frequently Asked Questions
Does Deerfield Management own MEDP?
No. Deerfield Management exited their position in Medpace Holdings Inc. (MEDP) in Q3 2025. They previously held the stock for 2 quarters.
How many hedge funds own MEDP?
2 specialist biotech hedge funds currently hold MEDP, including OrbiMed Advisors, Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy MEDP?
Deerfield Management's position in MEDP was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's MEDP position increasing or decreasing?
Deerfield Management completely exited their MEDP position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MEDPCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →